A thyroid podcast quietly became a hormone and longevity podcast.

Core thyroid talk fell by two thirds.

Every episode still mentions the thyroid. That never wavers: 100% of episodes, every single year. But mention density tells a different story than mention presence. Measured as share of all words spoken, thyroid vocabulary dropped from 155 mentions per 10,000 words in 2020 to a floor of 49 in 2024.

What replaced it arrived in two waves. Menopause and hormone replacement climbed steadily from 2020. Longevity and biohacking stayed near zero until 2022, then accelerated hard.

One drug class rewrote the second half of the archive.

GLP-1 agonists (Ozempic, Mounjaro, Wegovy and their peers) do not appear anywhere in the first two years of the show. The first mention lands in August 2022. By the most recent quarter, the topic runs at 13.4 mentions per 10,000 words, making it denser than any subject except the thyroid itself.

Presence spread even faster than density. In 2022, 6% of episodes touched GLP-1 drugs. In 2026, 57% do.

The supplement shelf turned over completely.

Comparing 2020 and 2021 against 2025 and 2026 surfaces a near total replacement of the show's practical vocabulary. The terms that vanished are not incidental. Berberine, metformin, leptin and iron were the load-bearing concepts of the early show.

Multiples compare average mention rate in 2020 and 2021 against 2025 and 2026. Only terms appearing at least 180 times across the corpus are included.

Five moments where the shift is legible.

Each of these is the first appearance of a term that later became routine, located to the episode.

Episodes got two and a half times longer.

The 2020 show was a short-form explainer with a median runtime of 18 minutes. It settled into a long-form interview format by 2024 and has stayed there. Publishing cadence held remarkably steady throughout at roughly 107 episodes a year, so the growth is entirely in depth rather than volume.

How this was measured.